Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the sixteen analysts that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, three have given a hold rating, ten have ass